Positive spillover effects of prescribing requirements: Increased cardiac testing in patients treated with trastuzumab for HER2+ metastatic breast cancer

Internal Medicine Journal

Volumn 42, Issue 11, 2012, Pages 1229-1235

  Lu, C Y ^a   Srasuebkul, P ^b   Drew, A K ^b   Ward, R L ^b   Pearson, S A ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Breast cancer; Cardiotoxicity; Data linkage; Drug safety; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST METASTASIS; DRUG EFFECT; DRUG SAFETY; ECHOCARDIOGRAPHY; FEMALE; HEART FUNCTION TEST; HUMAN; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL, HUMANIZED; AUSTRALIA; BREAST NEOPLASMS; CANCER CARE FACILITIES; CARDIOMYOPATHIES; CHEMOTHERAPY, ADJUVANT; DRUG MONITORING; ECHOCARDIOGRAPHY; FEMALE; GATED BLOOD-POOL IMAGING; GUIDELINE ADHERENCE; HEART FUNCTION TESTS; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MOLECULAR TARGETED THERAPY; NATIONAL HEALTH PROGRAMS; NEOPLASM PROTEINS; RECEPTOR, ERBB-2;

EID: 84869766893     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2011.02604.x     Document Type: Article

References (26)

1. Australian Institute of Health and Welfare and National Breast and Ovarian Centre. Breast cancer in Australia: an overview, 2009. Cancer series no. 50. Cat. no. CAN 46. Canberra: Australian Institute of Health and Welfare (AIHW), 2009.
2. UK National Institute for Health and Clinical Excellence. Early and locally advanced breast cancer: diagnosis and treatment (clinical guideline 80). London, 2009. Available from URL: http://guidance.nice.org.uk/CG80
3. UK National Institute for Health and Clinical Excellence. Advanced breast cancer: diagnosis and treatment (clinical guideline 81). London, 2009. Available from URL http://guidance.nice.org.uk/CG81
4. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M etal. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20: 1215-1221.
5. Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR etal. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 2006; 24: 4107-4115.
6. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE etal. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
7. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I etal. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
8. Australian National Breast Cancer Centre. Recommendations for Use of Trastuzumab (Herceptin) for the Treatment of HER2-Positive Breast Cancer. Sydney: Australian National Breast Cancer Centre; 2007.
9. Australian Government Department of Health and Ageing. Schedule of Pharmaceutical Benefits. 2010 [cited 2010 Oct 5]. Available from URL: http://www.pbs.gov.au/
10. McArthur HL, Chia S. Cardiotoxicity of trastuzumab in clinical practice. N Engl J Med 2007; 357: 94-95.
11. Extra JM, Antoine EC, Vincent-Salomon A, Delozier T, Kerbrat P, Bethune-Volters A etal. Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist 2010; 15: 799-809.
12. Pearson SA, Ringland CL, Ward RL. Trastuzumab and metastatic breast cancer: trastuzumab use in Australia - monitoring the effect of an expensive medicine access program. J Clin Oncol 2007; 25: 3688-3693.
13. Bengala C, Zamagni C, Pedrazzoli P, Matteucci P, Ballestrero A, Da Prada G etal. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study. Br J Cancer 2006; 94: 1016-1020.
14. Andersson J, Linderholm B, Greim G, Lindh B, Lindman H, Tennvall J etal. A population-based study on the first forty-eight breast cancer patients receiving trastuzumab (Herceptin) on a named patient basis in Sweden. Acta Oncol 2002; 41: 276-281.
15. Valuck RJ, Libby AM, Orton HD, Morrato EH, Allen R, Baldessarini RJ. Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry 2007; 164: 1198-1205.
16. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000; 19: 335-351.
17. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002; 27: 299-309.
18. Pearson SA, Soumerai S, Mah C, Zhang F, Simoni-Wastila L, Salzman C etal. Racial disparities in access after regulatory surveillance of benzodiazepines. Arch Intern Med 2006; 166: 572-579.
19. Lu CY, Soumerai SB, Ross-Degnan D, Zhang F, Adams AS. Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness. Med Care 2010; 48: 4-9.
20. Breen CL, Degenhardt LJ, Bruno RB, Roxburgh AD, Jenkinson R. The effects of restricting publicly subsidised temazepam capsules on benzodiazepine use among injecting drug users in Australia. Med J Aust 2004; 181: 300-304.
21. Tuma RS. Trastuzumab trials steal show at ASCO meeting. J Natl Cancer Inst 2005; 97: 870-871.
22. Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S etal. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol 2010; 28: 3422-3428.
23. Russell SD, Blackwell KL, Lawrence J, Pippen JE Jr, Roe MT, Wood F etal. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 2010; 28: 3416-3421.
24. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V etal. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005; 23: 7820-7826.
25. Jones AL, Barlow M, Barrett-Lee PJ, Canney PA, Gilmour IM, Robb SD etal. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 2009; 100: 684-692.
26. Olver IN, Haines IE. What changes are needed to the current direction and interpretation of clinical cancer research to meet the needs of the 21st century? Med J Aust 2009; 190: 74-77.